Open AccessPossibilities of PET/CT with 18F-PSMA-1007 in the Diagnosis of Triple Negative Breast Cancer: a Case Study
Author(s) -
А. В. Парнас,
А. А. Оджарова,
А. И. Пронин,
В. С. Ильяков,
Н. А. Мещерякова,
З. Х. Камолова,
Д. И. Невзоров
Publication year - 2021
Publication title -
onkologičeskij žurnal: lučevaâ diagnostika, lučevaâ terapiâ
Language(s) - English
Resource type - Journals
eISSN - 2713-167X
pISSN - 2587-7593
DOI - 10.37174/2587-7593-2021-4-4-88-92
Subject(s) - triple negative breast cancer , medicine , breast cancer , prostate cancer , estrogen receptor , cancer , progesterone receptor , oncology
Breast cancer (BC) is one of the most common cancers and the leading cause of cancer death in women. Triple negative breast cancer (TNBC) is a specific subtype of breast cancer that does not express estrogen receptors (ER), progesterone receptors (RP) or human epidermal growth factor receptor-2 (HER-2), has certain clinical features, a tendency to relapses and poor prognosis. Various studies demonstrate that prostate-specific antigen (PSA) is not strictly specific for prostate cancer, and can be produced by other tumor pathologies. In routine practice, PET/CT for TNBC is performed with 18 F-FDG. However PET/CT with 18 F-PSMA-1007 can be used as the method of choice with high theranostic potential. Here is a clinical case of a patient with TNBC who underwent PET/CT with 18 F-FDG and 18 F-PSMA-1007.